GLSI
NASDAQ
US
Greenwich LifeSciences, Inc. - Common stock
$22,82
▼ $-0,14
(-0,61%)
Vol. 54K
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$291.1M
ROE
-1042,8%
D/E
0,00
Beta
1,59
52W
$8–$22
Consenso Wall Street
8 analisti · Apr 20262
Acquisto forte
5
Compra
1
Mantieni
0
Vendi
0
Vendita forte
87,5%
Rating Compra
Grafico dei Prezzi
Titoli simili
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
PALI
Palisade Bio Inc
$350.2M
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
Utili
Tasso di battuta: 25,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Set 2025 | $-0,30 | $-0,30 | +$0,00 |
| Giu 2025 | $-0,24 | $-0,30 | $-0,06 |
| Mar 2025 | $-0,24 | $-0,25 | $-0,01 |
| Dic 2024 | $-0,21 | $-0,61 | $-0,40 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$2.7M | -$8.0M | -$3.3M | -$4.0M | -$4.2M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -700.9% | -700.9% | -700.9% | -700.9% | -700.9% | -1042.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.85 | 1.85 | 1.85 | 1.85 | 1.85 | 2.35 |
Rapporti chiave
ROA (TTM)
-565,5%
P/B
58,3
EPS (TTM)
$-1,46
CF/Share
$-0,48
52W High
$22,31
52W Low
$7,78
$7,78
Intervallo 52 settimane
$22,31
Salute finanziaria
Flusso di cassa libero
-$2.7M
Liquidità
$3.8M
Aggiornato al Set 30, 2025
Як GLSI виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка GLSI vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
58,3
▲
2268%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість GLSI vs аналоги Biotechnology
ROE
-1042,8%
▼
1449%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-565,5%
▼
1111%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя GLSI vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
2,4
▼
47%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,6
▲
64%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів GLSI
GLSI
Mediana peer
Industria
GLSI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
GLSI vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
PATEL SNEHAL
Chief Executive Officer · Gen 13
1800 shs
PATEL SNEHAL
Chief Executive Officer · Gen 12
2900 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 7,25%Blackrock Inc.
2,68%
$8.3M
Vanguard Group Inc
2,14%
$6.6M
Geode Capital Management, L…
1,09%
$3.4M
State Street Corporation
0,71%
$2.2M
Credit Agricole S.A.
0,63%
$1.9M
Aggiornato al Dic 31, 2025